Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 57-62 , January 2006

Clearance of Prions During Plasma Protein Manufacture

References 

  1. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion. 1998;38:810–816
  2. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 1999;39:1169–1178
  3. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet. 2000;356:999–1000
  4. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J. Gen. Virol. 2002;83:2897–2905
  5. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004;363:417–421
  6. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–529
  7. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: Specific preventative strategies. Blood Rev. 2000;14:94–110
  8. Prusiner SB, McKinley MP, Groth DF, et al. Scrapie agent contains a hydrophobic protein. Proc. Natl. Acad. Sci. U. S. A. 1981;78:6675–6679
  9. Prusiner SB, McKinley MP, Bowman KA, et al. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell. 1983;35:349–358
  10. Cai K, Miller JL, Stenland CJ, et al. Solvent-dependent precipitation of prion protein. Biochim. Biophys. Acta. 2002;1597:28–35
  11. Stenland CJ, Lee DC, Brown P, et al. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion. 2002;42:1497–1500
  12. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 2000;78:86–95
  13. Van Holten RW, Autenrieth S, Boose JA, et al. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion. 2002;42:999–1004
  14. Lee DC, Stenland CJ, Miller JL, et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion. 2001;41:449–455
  15. Van Holten RW, Autenrieth SM. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang. 2003;85:20–24
  16. Foster PR, McLean C, Welch AG, et al. Removal of abnormal prion protein by plasma fractionation. Transfus. Sci. 2000;22:53–56
  17. Gregori L, Maring JA, MacAuley C, et al. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals. 2004;32:1–10
  18. Ceroni M, Piccardo P, Safar J, et al. Scrapie infectivity and prion protein are distributed in the same pH range in agarose isoelectric focusing. Neurology. 1990;40:508–513
  19. Vey M, Baron H, Weimer T, et al. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals. 2002;30:187
  20. Lee DC, Stenland CJ, Hartwell RC, et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J. Virol. Methods. 2000;84:77–89
  21. Safar J, Wille H, Itri V, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat. Med. 1998;4:1157–1165
  22. Bellon A, Seyfert-Brandt W, Lang W, et al. Improved conformation-dependent immunoassay: Suitability for human prion detection with enhanced sensitivity. J. Gen. Virol. 2003;84:1921–1925
  23. Safar JG, Geschwind MD, Deering C, et al. Diagnosis of human prion disease. Proc. Natl. Acad. Sci. U. S. A. 2005;102:3501–3506
  24. Hartwell RC, Nelson MS, Kislan MM, et al. An improved Western blot assay to assess the clearance of prion protein from plasma-derived therapeutic proteins. J. Virol. Methods. 2005;125:187–193
  25. McLeod AH, Murdoch H, Dickinson J, et al. Proteolytic inactivation of the bovine spongiform encephalopathy agent. Biochem. Biophys. Res. Commun. 2004;317:1165–1170
  26. Bosque PJ, Prusiner SB. Cultured cell sublines highly susceptible to prion infection. J. Virol. 2000;74:4377–4386
  27. Cronier S, Laude H, Peyrin JM. Prions can infect primary cultured neurons and astrocytes and promote neuronal cell death. Proc. Natl. Acad. Sci. U. S. A. 2004;101:12271–12276
  28. Klohn PC, Stoltze L, Flechsig E, et al. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc. Natl. Acad. Sci. U. S. A. 2003;100:11666–11671

PII: S0887-7963(05)00082-9

doi: 10.1016/j.tmrv.2005.08.005

Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 57-62 , January 2006

Article Tools

* Image Usage & Resolution